检索结果-南通市图书馆

Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy

Chinese Journal of Cancer Research 2013年第3期25卷 274-280页

作者： Costanza Chiumento Alba Fiorentino Mariella Cozzolino Rocchina Caivano Stefania Clemente Piernicola Pedicini Vincenzo Fusco Department of Radiation Oncology IRCCS-CROBRionero in Vulture 85028 Italy

Objective： To analyze the correlations among comorbidity and overall survival （OS）, biochemical progression-free survival （b-PFS） and toxicity in elderly patients with localized prostate cancer treated with 125I brachytherapy. Methods： Elderly men, aged ≥65 years, with low-intermediate risk prostate cancer, were treated with permanent 125I brachytherapy as monotherapy. Comorbidity data were obtained from medical reports using age-adjusted Charlson comorbidity index （a-CCI）. The patients were categorized into two age groups （〈75 and 〉75 years old）, and two comorbidity score groups （a-CCI ≤3 and 〉3）. Toxicity was scored with Radiation Therapy Oncology Group （RTOG） scale. Results： From June 2003 to October 2009, a total of 92 elderly patients underwent prostate brachytherapy, including 57 men （62%） with low-risk prostate cancer, and 35 men （38%） with intermediate-risk prostate cancer. The median age of patients was 75 years （range, 65-87 years）. Forty-seven patients （51%） bad a-CCI _〈3 and 45 patients （49%） a-CCI 〉3. With a median follow-up period of 56 months （range, 24-103 months）, the 5-year actuarial OS and b-PFS were 91.3% and 92.4% respectively, without statistical significance between two Charlson score groups. Toxicity was mild. None of the patients experienced gastrointestinal （GI） toxicity, and only 4 patiens （4%） experienced late genitourinary （GU） grade-3 （G3） toxicity. No correlation between acute GU and GI toxicity and eomorbidity was showed （P=0.50 and P=0.70, respectively）. Conclusions： Our data suggest that elderly men with low-intermediate risk prostate cancer and comorbidity can be considered for a radical treatment as 12Sl low-dose rate brachytherapy.

关键词： Prostate cancer braehytherapy elderly comorbidity toxicity overall survival biochemical control

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Dose escalation of external beam radiotherapy for high-risk prostate cancerdImpact of multiple high-risk factor

引用

Asian Journal of Urology 2019年第2期6卷 192-199页

作者： Rei Umezawa Koji Inaba Satoshi Nakamura Akihisa Wakita Hiroyuki Okamoto Keisuke Tsuchida Tairo Kashihara Kazuma Kobayashi Ken Harada Kana Takahashi Naoya Murakami Yoshinori Ito Hiroshi Igaki Keiichi Jingu Jun Itami Department of Radiation Oncology National Cancer Center HospitalChuo-kuTokyoJapan Department of Radiation Oncology Tohoku University Graduate School of MedicineSendaiJapan

Objective:To retrospectively investigate the treatment outcomes of external beam radiotherapy with androgen deprivation therapy(ADT)in high-risk prostate cancer in three radiotherapy dose ***:Between 1998 and 2013,patients with high-risk prostate cancer underwent threedimensional conformal radiotherapy or intensity-modulated radiotherapy of 66 Gy,72 Gy,or 78 Gy with ***-specific antigen(PSA)relapse was defined using the Phoenix *** relapse-free survival(PRFS)was evaluated in each radiotherapy dose ***,high-risk patients were divided into H-1(patients with multiple high-risk factors)and H-2(patients with a single high-risk factor)as risk ***:Two hundred and eighty-nine patients with a median follow-up period of 77.3 months were analyzed in this *** median duration of ADT was 10.1 ***,Gleason score,T stage,and radiotherapy dose influenced PRFS with statistical significance both in univariate and multivariate *** 4-year PRFS rates in Group-66 Gy,Group-72 Gy and Group-78 Gy were 72.7%,81.6%and 90.3%,*** rates in the H-1 subgroup differed with statistical significance with an increasing radiotherapy dose having a more favorable PRFS,while PRFS rates in H-2 subgroup did not differ with increase in radiotherapy ***:Dose escalation for high-risk prostate cancer in combination with ADT improved *** for patients in the H-1 subgroup was poor,but dose escalation in those patients was beneficial,while dose escalation in the H-2 subgroup was not proven to be effective for improving PRFS.

关键词： Prostate cancer External beam radiotherapy Dose escalation biochemical control

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：